{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:40:05Z","timestamp":1746330005696,"version":"3.40.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,8,9]],"date-time":"2014-08-09T00:00:00Z","timestamp":1407542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00280-014-2556-z","type":"journal-article","created":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T05:29:38Z","timestamp":1407475778000},"page":"765-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A pharmacodynamic model of Bcr\u2013Abl signalling in chronic myeloid leukaemia"],"prefix":"10.1007","volume":"74","author":[{"given":"Robert C.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Radivoyevitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,9]]},"reference":[{"key":"2556_CR1","first-page":"4","volume":"7","author":"RC Jackson","year":"2013","unstructured":"Jackson RC, Radivoyevitch T (2013) Modelling c-Abl signalling in activated neutrophils: the anti-inflammatory effect of seliciclib. Biodiscovery 7:4. doi: 10.7750\/BioDiscovery.2013.7.4","journal-title":"Biodiscovery"},{"key":"2556_CR2","first-page":"88","volume-title":"Structure and function in cell signalling","author":"J Nelson","year":"2008","unstructured":"Nelson J (2008) Structure and function in cell signalling. Wiley, Chichester, pp 88\u201389"},{"key":"2556_CR3","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1038\/sj.onc.1206607","volume":"22","author":"P Coppo","year":"2003","unstructured":"Coppo P, Dusanter-Fourt I, Millot G et al (2003) Constitutive and specific activation of STAT3 by Bcr\u2013Abl in embryonic stem cells. Oncogene 22:4102\u20134110","journal-title":"Oncogene"},{"key":"2556_CR4","unstructured":"Nair RJ, Tolentino JH, Hazlehurst LA (2012) Role of STAT3 in transformation and drug resistance in CML. Front Oncol 2:1\u201312. doi: 10.3389\/fonc2012.00030"},{"key":"2556_CR5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.20062335","volume":"204","author":"RA Etten Van","year":"2007","unstructured":"Van Etten RA (2007) Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 204:461\u2013465","journal-title":"J Exp Med"},{"key":"2556_CR6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"189","author":"K Nieborowska-Skorska","year":"1999","unstructured":"Nieborowska-Skorska K, Wasik MA, Slupianek A et al (1999) Signal transducer and activator of transcription (STAT5) activation by BCR\u2013ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\u2013ABL and is required for leukemogenesis. J Exp Med 189:1229\u20131242","journal-title":"J Exp Med"},{"key":"2556_CR7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-06-0446","volume":"6","author":"S Nam","year":"2007","unstructured":"Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R (2007) Dasatinib (BMS-354825) inhibits STAT5 signaling associated with apoptosis in chronic myologenous leukemia cells. Mol Cancer Ther 6:1400\u20131405","journal-title":"Mol Cancer Ther"},{"key":"2556_CR8","doi-asserted-by":"crossref","unstructured":"Casetti L, Martin-Lanner\u00e9e S, Najjar I, Plo I, Aug\u00e9 S, Roy L, Chomel J-C, Laret E, Turhan AG, Dusanter-Fourt I (2013) Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem\/progenitor cells. Cancer Res 73(7):2052\u20132058. doi: 10.1158\/0008-5472.CAN-12-3955","DOI":"10.1158\/0008-5472.CAN-12-3955"},{"key":"2556_CR9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2012.19","volume":"26","author":"AR Soliera","year":"2012","unstructured":"Soliera AR, Mariani SA, Audia A et al (2012) Gfi-1 inhibits proliferation and colony formation of p210BCR\/ABL-expressing cells via transcriptional repression of STAT5 and Mcl-1. Leukemia 26:1555\u20131563","journal-title":"Leukemia"},{"key":"2556_CR10","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/sj.onc.1210979","volume":"27","author":"WJ Tao","year":"2008","unstructured":"Tao WJ, Lin H, Samanta AK, Arlinghaus R (2008) BCR\u2013ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene 27:3194\u20133200","journal-title":"Oncogene"},{"key":"2556_CR11","first-page":"331","volume":"38","author":"J Lee","year":"2008","unstructured":"Lee J, Kim Y, Lim J, Kim M, Han K (2008) G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia. Ann Clin Lab Sci 38:331\u2013337","journal-title":"Ann Clin Lab Sci"},{"key":"2556_CR12","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","volume":"119","author":"M Nieborowska-Skorska","year":"2012","unstructured":"Nieborowska-Skorska M, Kopinski PK, Ray R et al (2012) RAC2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 119:4253\u20134263","journal-title":"Blood"},{"key":"2556_CR13","first-page":"130","volume-title":"Cell signalling","author":"JT Hancock","year":"2010","unstructured":"Hancock JT (2010) Cell signalling, 3rd edn. Oxford University Press, Oxford, p 130","edition":"3"},{"key":"2556_CR14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0021-9258(18)48474-8","volume":"267","author":"KC Cheng","year":"1992","unstructured":"Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb L (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G\u00a0\u2192\u00a0T and A\u00a0\u2192\u00a0C substitutions. J Biol Chem 267:166\u2013172","journal-title":"J Biol Chem"},{"key":"2556_CR15","first-page":"1","volume":"1","author":"RC Jackson","year":"2012","unstructured":"Jackson RC (2012) Modelling malignant progression with a finite state machine supports a two checkpoint theory of cancer. Biodiscovery 1:1\u201310","journal-title":"Biodiscovery"},{"key":"2556_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01273744","volume":"1","author":"SI Rubinow","year":"1975","unstructured":"Rubinow SI, Lebowitz JL (1975) A mathematical model of neutrophil production and control in normal man. J Math Biol 1:187\u2013225","journal-title":"J Math Biol"},{"key":"2556_CR17","first-page":"2084","volume":"51","author":"AS Fokas","year":"1991","unstructured":"Fokas AS, Keller JB, Clarkson BD (1991) Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. Cancer Res 51:2084\u20132091","journal-title":"Cancer Res"},{"issue":"9","key":"2556_CR18","doi-asserted-by":"crossref","first-page":"e1000503","DOI":"10.1371\/journal.pcbi.1000503","volume":"5","author":"J Foo","year":"2009","unstructured":"Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 5(9):e1000503. doi: 10.1371\/journal.pcbi.1000503","journal-title":"PLoS Comput Biol"},{"key":"2556_CR19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jtbi.2011.10.017","volume":"293","author":"C Zhuge","year":"2012","unstructured":"Zhuge C, Lei J, Mackey MC (2012) Neutrophil dynamics in response to chemotherapy and G-CSF. J Theor Biol 293:111\u2013120","journal-title":"J Theor Biol"},{"key":"2556_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jtbi.2012.08.028","volume":"315","author":"G Brooks","year":"2012","unstructured":"Brooks G, Provencher G, Lei J, Mackey MC (2012) Neutrophil dynamics after chemotherapy and G-CSF: the role of pharmacokinetics in shaping the response. J Theor Biol 315:97\u2013109","journal-title":"J Theor Biol"},{"key":"2556_CR21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-4682-9-32","volume":"9","author":"M Scholz","year":"2012","unstructured":"Scholz M, Schirm S, Wetzler M, Engel C, Loeffler M (2012) Pharmacokinetic and-dynamic modelling of G-CSF derivatives in humans. Theor Biol Med Model 9:32\u201360","journal-title":"Theor Biol Med Model"},{"key":"2556_CR22","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-09-381855","volume":"119","author":"T Radivoyevitch","year":"2012","unstructured":"Radivoyevitch T, Hlatky L, Landaw J, Sachs RK (2012) Quantitative modeling of chronic myeloid leukemia: insights from radiobiology. Blood 119:4363\u20134371","journal-title":"Blood"},{"key":"2556_CR23","doi-asserted-by":"crossref","DOI":"10.1201\/9781420054194","volume-title":"Computer techniques in preclinical and clinical drug development","author":"RC Jackson","year":"1996","unstructured":"Jackson RC (1996) Computer techniques in preclinical and clinical drug development. CRC Press, Boca Raton"},{"key":"2556_CR24","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for CML. Blood 105:2640\u20132653","journal-title":"Blood"},{"key":"2556_CR25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"2556_CR26","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr\u2013Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505","journal-title":"Cancer Res"},{"key":"2556_CR27","first-page":"166","volume-title":"Pharmacokinetics: processes and mathematics","author":"PG Welling","year":"1986","unstructured":"Welling PG (1986) Pharmacokinetics: processes and mathematics. American Chemical Society, Washington, p 166"},{"key":"2556_CR28","volume-title":"An introduction to R","author":"WN Venables","year":"2005","unstructured":"Venables WN, Smith DM (2005) An introduction to R. Network Theory Ltd, Bristol"},{"key":"2556_CR29","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T et al (2007) Bcr\u2013Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242\u20132248","journal-title":"Blood"},{"key":"2556_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17460441.3.1.131","volume":"3","author":"RC Jackson","year":"2008","unstructured":"Jackson RC, Barnett AL, McClue SJ, Green SR (2008) Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases. Expert Opin Drug Discov 3:131\u2013143","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"2556_CR31","doi-asserted-by":"crossref","first-page":"e30128","DOI":"10.1371\/journal.pone.0030128","volume":"7","author":"K Wang","year":"2012","unstructured":"Wang K, Hampson P, Hazeldine J et al (2012) Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis. PLoS ONE 7(1):e30128. doi: 10.1371\/journal.pone.0030128","journal-title":"PLoS ONE"},{"key":"2556_CR32","first-page":"5318","volume":"50","author":"WR Greco","year":"1990","unstructured":"Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-\u03b2-D-arabinofuranosylcytosine. Cancer Res 50:5318\u20135327","journal-title":"Cancer Res"},{"key":"2556_CR33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331\u2013385","journal-title":"Pharmacol Rev"},{"key":"2556_CR34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.coph.2012.01.015","volume":"12","author":"I Rahman","year":"2012","unstructured":"Rahman I, MacNee W (2012) Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 12:256\u2013265","journal-title":"Curr Opin Pharmacol"},{"key":"2556_CR35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2008.74","volume":"22","author":"H Zhang","year":"2008","unstructured":"Zhang H, Trachootham D, Wu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P (2008) Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22:1191\u20131199","journal-title":"Leukemia"},{"key":"2556_CR36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","volume":"53","author":"P Coutre Le","year":"2004","unstructured":"Le Coutre P, Kreutzer KA, Pursche S, Bonin MV et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313\u2013323","journal-title":"Cancer Chemother Pharmacol"},{"key":"2556_CR37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894","journal-title":"Clin Pharmacokinet"},{"key":"2556_CR38","first-page":"77","volume":"19","author":"D Leveque","year":"2005","unstructured":"Leveque D, Maloissel F (2005) Clinical pharmacokinetics of imatinib mesylate. In Vivo 19:77\u201384","journal-title":"In Vivo"},{"key":"2556_CR39","unstructured":"Faivre S, Pierga JY, Delbado C et al (2003) A phase I and pharmacokinetic trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor in patients with advanced solid tumours: exploration of three administration schedules. Abstracts, EORTC-NCI-AACR meeting, Boston, USA"},{"key":"2556_CR40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5414\/CPP42232","volume":"42","author":"S Motte De La","year":"2004","unstructured":"De La Motte S, Gianella-Borradori A (2004) Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 42:232\u2013239","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2556_CR41","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","volume":"118","author":"M Tang","year":"2011","unstructured":"Tang M, Gonen M, Quintas-Cardama A et al (2011) Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 118:1622\u20131631","journal-title":"Blood"},{"key":"2556_CR42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mrgentox.2010.07.013","volume":"703","author":"WA Beard","year":"2010","unstructured":"Beard WA, Batra VK, Wilson SH (2010) DNA polymerase structure-based insight on the mutagenic properties of 8-oxoguanine. Mutat Res 703:18\u201323","journal-title":"Mutat Res"},{"key":"2556_CR43","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V et al (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103:2794\u20132799","journal-title":"Proc Natl Acad Sci USA"},{"key":"2556_CR44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.1964.94","volume":"18","author":"KR Harrap","year":"1964","unstructured":"Harrap KR, Speed DEM (1964) Some biochemical aspects of leukaemias: the appearance of a soluble disulphide in the blood in chronic granulocytic leukaemia. Br J Cancer 18:809\u2013817","journal-title":"Br J Cancer"},{"key":"2556_CR45","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1038\/sj.onc.1206626","volume":"22","author":"T Harnois","year":"2003","unstructured":"Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bournmeyster N (2003) Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Oncogene 22:6445\u20136454","journal-title":"Oncogene"},{"key":"2556_CR46","first-page":"3998","volume":"53","author":"RC Jackson","year":"1993","unstructured":"Jackson RC (1993) Amphibolic drug combinations: the design of selective antimetabolite protocols based upon the kinetic properties of multienzyme systems. Cancer Res 53:3998\u20134003","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2556-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2556-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2556-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:19:24Z","timestamp":1746328764000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2556-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,9]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["2556"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2556-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2014,8,9]]}}}